STOCK TITAN

Generex Biotechnology Announces Corporate Update and Investor Conference Call: NuGenerex Immuno-Oncology on Thursday October 8, 2020 at 8:00 AM

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Generex Biotechnology Corporation (OTCQB:GNBT) announced an investor conference call on Thursday, October 8, 2020, at 8:00 AM Eastern time. Key topics include a licensing agreement with Bintai Kinden for a COVID-19 vaccine and updates on ongoing initiatives. CEO Joseph Moscato will discuss plans for the listing of NuGenerex Immuno-Oncology and advancements in their Ii-Key technology platform. Generex emphasizes their focus on generating immunotherapies and vaccines, particularly in response to the pandemic's challenges.

Positive
  • Signed licensing and distribution agreement with Bintai Kinden for COVID-19 vaccine development.
  • Advancement of Ii-Key vaccine through clinical and regulatory processes.
Negative
  • None.

MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for tomorrow’s investor conference call on Thursday October 8, 2020 at 8:00 AM Eastern time.

The access information for the investor conference call is as follows:
Domestic US/Canada – 1-877-830-2587
Direct Toll / International - 1-785-424-1734

Program Title: NuGenerex Immuno-Oncology - Investor Conference Call
Conference ID – 30417

Agenda

  • Signed licensing and distribution agreement with Bintai Kinden for the development of Ii-Key-SARS-CoV-2 vaccine against COVID-19
  • COVID-19 Vaccine Scientific and Clinical Advisory Board
  • Status of COVID-19 Vaccine international initiatives
  • NuGenerex Immuno-Oncology Listing Plans

On the call, Generex President & Chief Executive Officer, Joseph Moscato and his team will provide an overview of NuGenerex Immuno-Oncology and the company’s development efforts for a COVID-19 vaccine using the Ii-key technology to create a “Complete Vaccine” that activates a targeted, neutralizing antibody response and a cellular response that can provide the long term immune memory that is essential to stopping this devastating pandemic.

Mr. Moscato said, “I look forward to speaking with our shareholders to discuss the listing of NuGenerex Immuno-Oncology on a national exchange and our plans to expand the Ii-Key technology platform to generate new immunotherapies and vaccines. We have a number of exciting initiatives that I am eager to present, and our closing of the Bintai Kinden licensing and distribution agreement for our COVID-19 Complete Vaccine. We are excited that we now have the money to advance our Ii-Key vaccine through the clinical and regulatory process, and as always, we welcome questions from shareholders during the call.”

About NuGenerex Immuno-Oncology
NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate, independent public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer.

About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato
646-599-6222

Todd Falls
1-800-391-6755 Extension 222
investor@generex.com

FAQ

What is the purpose of the Generex Biotechnology conference call on October 8, 2020?

The conference call aims to discuss updates on COVID-19 vaccine development, a licensing agreement with Bintai Kinden, and the listing plans for NuGenerex Immuno-Oncology.

What is the significance of the agreement with Bintai Kinden for Generex Biotechnology?

The agreement allows Generex to advance the development of its COVID-19 vaccine, which is crucial for their clinical and regulatory progress.

Who will be speaking during the Generex conference call?

Generex President & CEO Joseph Moscato will lead the call along with his team to provide insights into the company’s initiatives.

What are the key topics expected to be covered in the investor conference call?

Topics include the licensing agreement for the COVID-19 vaccine, updates on clinical initiatives, and plans for the NuGenerex Immuno-Oncology listing.

What technology is Generex Biotechnology utilizing for its vaccine development?

Generex is using its Ii-Key technology platform to create a 'Complete Vaccine' targeting COVID-19.

GNBT

OTC:GNBT

GNBT Rankings

GNBT Latest News

GNBT Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Miramar